Skip to main content
Ibrutinib+BR a promising treatment option for newly diagnosed MCL ineligible for intensive therapy
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Ibrutinib+BR a promising treatment option for newly diagnosed MCL ineligible for intensive therapy
User login
Username
Password
Reset your password
Concept
Lead
score
Mantle Cell Lymphoma
1
1
Prognosis
0
0.85
Biologic Therapy
0
0.82
Antineoplastic Drug
0
0.8
Monoclonal Antibody
0
0.8
Lymphoma
0
0.4
Proteasome Inhibitor
0
0.2
Specialty
Lead
score
Hematology-Oncology
1
1
Pharmacist
0
1
Edit Tags